TSC Ratings' Updates: Enzon Pharma
TSC Ratings provides exclusive stock, ETF and mutual fund ratings and commentary based on award-winning, proprietary tools. Its "safety first" approach to investing aims to reduce risk while seeking solid outperformance on a total return basis.
The following ratings changes were generated on Wednesday, May 20.
We've upgraded Enzon Pharmaceuticals (ENZN) from sell to hold. Strengths include the company's increase in net income and expanding profit margins. However, we also find weaknesses including a decline in the stock price during the past year, generally poor debt management and disappointing return on equity.
Net income rose 307.6% compared with the same quarter last year, from $1.5 million to $6.2 million. Enzon's gross profit margin of 77.2% has increased from the year-ago quarter, but its 12.7% net profit margin trails the industry average. Revenue fell 0.3% since the year-ago quarter, though EPS increased. The debt-to-equity ratio or 5 is above the industry average, but the quick ratio of 4.6 implies an ability to cover short-term cash needs. Return on equity has decreased compared with the same quarter last year.We've upgraded Fluor (FLR) from hold to buy, driven by its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, compelling growth in net income and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Revenue rose by 20.6% since the same quarter last year, and EPS are up, though we anticipate underperformance in the coming year relative to the company's two-year pattern of positive EPS growth. Fluor's debt-to-equity ratio of 0.1 is below the industry average, and its quick ratio of 1.1 implies an ability to avoid short-term cash problems. ROE has improved compared with the same quarter last year, and net income increased by 49.8%, from $136.7 million to $204.8 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV